Physician profile
Christine Mary Hoover
NPI 1942861778
$6,004.66
in general payments reported to CMS, 2019-2025
12 companies · $5,107 in 2025
The $5,107 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.33 · 2022: $202 · 2023: $511 · 2024: $107 · 2025: $5,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $1,514 · Travel and Lodging: $1,203 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $1,514.00 |
| Travel and Lodging | $1,202.87 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $4,787.03 | 2025 | |
| Medtronic, INC. | $253.64 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $186.48 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $132.00 | 2023 | Crysvita |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Lilly USA, LLC | $124.05 | 2022 | |
| Amgen INC. | $90.56 | 2025 | Evenity |
| Regeneron Healthcare Solutions, INC. | $83.14 | 2024 | Evkeeza |
| Corcept Therapeutics | $78.33 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $77.71 | 2022 | |
| Tandem Diabetes Care, INC. | $45.94 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $20.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.